Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

In March, Global Blood Therapeutics raised $240.5 million in net proceeds from a secondary offering. The cash and cash equivalents at the end of March stood at $544.6 million, as compared to $329. ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

The all-cash deal will see Pfizer acquire all outstanding shares of Global Blood Therapeutics for $68.50 per share; all told, the enterprise value of the arrangement is roughly $5.4 billion.

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

The global blood cancer therapeutics market is poised to grow by USD 12.63 billion during 2019-2023, progressing at a CAGR of over 8%.

Shares of rare-disease specialist Global Blood Therapeutics (GBT) are rising sharply for the second day in a row. As of 12:38 p.m. ET, the drugmaker's stock was up by a healthy 38.4%.

Shares of Global Blood Therapeutics, a biotech working on a treatment for sickle cell disease, shot up to $43.11 a share on Wednesday after the company's $120 million IPO topped its target range ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

In response to receiving Breakthrough Therapy Designation from the FDA on the company's lead compound, shares of Global Blood Therapeutics (NASDAQ: GBT) , a clinical-stage biotech focused on blood ...